Cargando…
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
IONIS‐FXI(RX) (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares the same RNA sequence as IONIS‐FXI(RX) but contains a G...
Autores principales: | Willmann, Stefan, Marostica, Eleonora, Snelder, Nelleke, Solms, Alexander, Jensen, Markus, Lobmeyer, Maximilian, Lensing, Anthonie W. A., Bethune, Claudette, Morgan, Erin, Yu, Rosie Z., Wang, Yanfeng, Jung, Shiangtung W., Geary, Richard, Bhanot, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376138/ https://www.ncbi.nlm.nih.gov/pubmed/34085768 http://dx.doi.org/10.1002/psp4.12663 |
Ejemplares similares
-
Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD
por: Walsh, Michael, et al.
Publicado: (2021) -
Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency
por: Harris, Victoria A., et al.
Publicado: (2021) -
Anticoagulant therapy in patients with congenital FXI deficiency
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021) -
Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020) -
BJTJ-1837, a novel FXI activation-blocking antibody
por: He, Xugang, et al.
Publicado: (2023)